Shanghai Allist Pharmaceuticals Co.,Ltd. (688578.SH) released its semi-annual report for 2025, showing strong financial performance during the reporting period. The company achieved revenue of 23.74 billion yuan, representing a year-on-year increase of 50.57%. Net profit attributable to shareholders reached 10.51 billion yuan, marking a substantial growth of 60.22% compared to the same period last year. Non-GAAP net profit totaled 9.05 billion yuan, up 39.92% year-on-year. Basic earnings per share stood at 2.34 yuan. The company has proposed a cash dividend distribution of 4.00 yuan per 10 shares (tax inclusive).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments